Canada Pension Plan Investment Board purchased a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 23,070 shares of the medical instruments supplier's stock, valued at approximately $8,282,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. Bank of Nova Scotia increased its stake in West Pharmaceutical Services by 337.8% in the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier's stock valued at $16,373,000 after purchasing an additional 50,402 shares during the last quarter. Hsbc Holdings PLC boosted its stake in West Pharmaceutical Services by 23.3% in the 4th quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier's stock worth $40,425,000 after buying an additional 27,745 shares during the last quarter. Renaissance Technologies LLC boosted its stake in West Pharmaceutical Services by 100.2% in the 1st quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier's stock worth $52,549,000 after buying an additional 104,924 shares during the last quarter. Conestoga Capital Advisors LLC grew its holdings in West Pharmaceutical Services by 6.7% in the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier's stock valued at $32,826,000 after buying an additional 8,179 shares during the period. Finally, Ilmarinen Mutual Pension Insurance Co purchased a new stake in West Pharmaceutical Services in the 4th quarter valued at about $3,027,000. 93.90% of the stock is currently owned by hedge funds and other institutional investors.
West Pharmaceutical Services Trading Down 2.3%
Shares of WST stock opened at $338.21 on Friday. The stock has a market cap of $23.80 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 2.36 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00. The firm's 50 day moving average price is $350.55 and its two-hundred day moving average price is $303.61.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. During the same quarter in the prior year, the business earned $1.84 earnings per share. The business's quarterly revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.
West Pharmaceutical Services Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services's dividend payout ratio is 11.27%.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the stock. Morgan Stanley increased their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an "equal weight" rating in a report on Thursday, July 9th. Barclays upgraded shares of West Pharmaceutical Services from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Zacks Research downgraded shares of West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 12th. TD Cowen reiterated a "buy" rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Finally, Weiss Ratings raised shares of West Pharmaceutical Services from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $368.08.
Get Our Latest Research Report on West Pharmaceutical Services
West Pharmaceutical Services Profile
(
Free Report)
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Featured Articles
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
